Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Issue 3 (September 2015)

• Record Type: Journal Article
• Authors: Shan, Ling; Wang, Ziping; Guo, Lei; Sun, Hongyan; Qiu, Tian; Ling, Yun; Li, Wenbin; Li, Lin; Liu, Xiuyun; Zheng, Bo; Lu, Ning; Ying, Jianming
• Is Part Of: Lung cancer. Volume 89:Issue 3(2015:Sep.)
• Page Start: 337
• Page End: 342
• Publication Date: 2015-09
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.06.008
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005"> <italic>EGFR</italic> mutation abundance is the fundamental cause for varied PFS from TKI treatment.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010"> <italic>EGFR</italic> amplification is contributed to <italic>EGFR</italic> mutation abundance in lung cancer.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Co-examination of <italic>EGFR</italic> amplification and mutation is optimal for TKI treatment.</p> </list-item> </list> </p> </sec> </abstract>